Blockage of tumor necrosis factor prevents intestinal mucosal inflammation through down-regulation of interleukin-23 secretion

Journal of Autoimmunity

Volumn 29, Issue 2-3, 2007, Pages 187-194

  Liu, Zhanju ^a   Jiu, Jinxia ^a   Liu, Shuman ^a   Fa, Xianen ^a   Li, Fuguang ^b   Du, Ying ^b  

^a Laboratory of Immunopathology   (China)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

Experimental colitis; Inflammatory bowel disease; Interleukin 17; Interleukin 23; Tumor necrosis factor

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 23P19; MESSENGER RNA; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; GENE EXPRESSION REGULATION; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; IN VIVO STUDY; INTESTINE MUCOSA; LAMINA PROPRIA; LYMPHOCYTE TRANSFER; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCID MOUSE; THERAPY DELAY; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD45; ANTIGENS, CD80; CD4-POSITIVE T-LYMPHOCYTES; COLITIS; COLON; DOWN-REGULATION; FEMALE; INFLAMMATORY BOWEL DISEASES; INTERFERON TYPE II; INTERLEUKIN-17; INTERLEUKIN-23 SUBUNIT P19; INTESTINAL MUCOSA; MICE; MICE, SCID; MUCOSITIS; TUMOR NECROSIS FACTORS;

EID: 34548531881     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2007.07.004     Document Type: Article

References (34)

1. Bouma G., and Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 3 (2003) 521-533
2. Sartor R.B. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 3 (2006) 390-407
3. Rahbar A., Bostrom L., and Soderberg-Naucler C. Detection of cytotoxic CD13-specific autoantibodies in sera from patients with ulcerative colitis and Crohn's disease. J Autoimmun 26 (2006) 155-164
4. Kollias G. TNF pathophysiology in murine models of chronic inflammation and autoimmunity. Semin Arthritis Rheum 34 5 suppl. 1 (2005) 3-6
5. Aringer M., and Smolen J.S. Tumor necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus 13 (2004) 344-347
6. Leonardi C.L., Powers J.L., Matheson R.T., Goffe B.S., Zitnik R., Wang A., et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349 (2003) 2014-2022
7. Hassan A., Fathi M., Dastmalchi M., Lundberg I.E., and Padyukov L. Genetically determined imbalance between serum levels of tumour necrosis factor (TNF) and interleukin (IL)-10 is associated with anti-Jo-1 and anti-Ro52 autoantibodies in patients with poly- and dermatomyositis. J Autoimmun 27 (2006) 62-68
8. Seko Y., Coke S., Kasprzak W., Shapiro B.A., and Ragheb J.A. The role of cytokine mRNA stability in the pathogenesis of autoimmune disease. Autoimmun Rev 5 (2006) 299-305
9. + T cells. Immunity 1 (1994) 553-562
10. Rutgeerts P., Van Assche G., and Vermeire S. Optimizing anti-TNF treatment inflammatory bowel disease. Gastroenterology 126 (2004) 1593-1610
11. + T cells by blocking the CD40-CD154 interactions. J Immunol 164 (2000) 6005-6014
12. Liu Z., Geboes K., Heremans H., Overbergh L., Mathieu C., Rutgeerts P., et al. Role of interleukin-12 in the induction of mucosal inflammation and abrogation of regulatory T cell function in chronic experimental colitis. Eur J Immunol 31 (2001) 1550-1560
13. Hue S., Ahern P., Buonocore S., Kullberg M.C., Cua D.J., McKenzie B.S., et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med 203 (2006) 2473-2483
14. Elson C.O., Cong Y., Weaver C.T., Schoeb T.R., McClanahan T.K., Fick R.B., et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-medicated model in mice. Gastroenterology 132 (2007) 2359-2370
15. Kikly K., Liu L., Na S., and Sedgwick J.D. The IL-23/Th17 axis: therapeutic targets for autoimmune inflammation. Curr Opin Immunol 18 (2006) 670-675
16. Furuzawa-Carballeda J., Vargas-Rojas M.I., and Cabral A.R. Autoimmune inflammation from the Th17 perspective. Autoimmun Rev 6 (2007) 169-175
17. Schulzke J.D., Bojarski C., Zeissig S., Heller F., Gitter A.H., and Fromm M. Disrupted barrier function through epithelial cell apoptosis. Ann NY Acad Sci 1072 (2006) 288-299
18. Ebert E.C. Tumour necrosis factor-α enhances intraepithelial lymphocyte proliferation and migration. Gut 42 (1998) 650-655
19. Van den Brande J.M., Koehler T.C., Zelinkova Z., Bennink R.J., te Velde A.A., ten Cate F.J., et al. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients of Crohn's disease. Gut 56 (2007) 509-517
20. Shen C., Assche G.V., Colpaert S., Maerten P., Geboes K., Rutgeerts P., et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 21 (2005) 251-258
21. Gottlieb A.B., Chamian F., Masud S., Cardinale I., Abello M.V., Lowes M.A., et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 175 (2005) 2721-2729
22. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201 (2005) 233-240
23. Abbas A.K., Lohr J., and Knoechel B. Balancing autoaggressive and protective T cell responses. J Autoimmun 28 (2007) 59-61
24. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., et al. Interleukin-23 rather than inteleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421 (2003) 744-748
25. Wiekowski M.T., Leach M.W., Evans E.W., Sullivan L., Chen S.C., Vassileva G., et al. Uniquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death. J Immunol 166 (2001) 7563-7570
26. Kullberg M.C., Jankovic D., Feng C.G., Hue S., Gorelick P.L., McKenzie B.S., et al. IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J Exp Med 203 (2006) 2485-2494
27. Schmidt C., Giese T., Ludwig B., Muller-Molaian I., Marth T., Zeuzem S., et al. Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm Bowel Dis 11 (2005) 16-23
28. Duerr R.H., Taylor K.D., Brant S.R., Rioux J.D., Silverberg M.S., Daly M.J., et al. A genome-wide association study identifies IL-23R as an inflammatory bowel disease gene. Science 314 (2006) 1461-1463
29. Ehrenstein M.R., Evans J.G., Singh A., Moore S., Warnes G., Isenberg D.A., et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J Exp Med 200 (2004) 277-285
30. Nadkarni S., Mauri C., and Ehrenstein M.R. Anti-TNF-α therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-β. J Exp Med 204 (2007) 33-39
31. Peng J., Dicker B., Du W., Tang F., Nguyen P., Geiger T., et al. Converting antigen-specific diabetogenic CD4 and CD8 T cells to TGF-β producing non-pathogenic regulatory cells following FoxP3 transduction. J Autoimmun 28 (2007) 188-200
32. Alvarado-Sanchez B., Hernandez-Castro B., Portales-Perez D., Baranda L., Layseca-Espinosa E., Abud-Mendoza C., et al. Regulatory T cell in patients with systemic lupus erythematosus. J Autoimmun 27 (2006) 110-118
33. Ban Y., Tozaki T., Tobe T., Ban Y., Jacobson E.M., Concepcion E.C., et al. The regulatory T cell gene FOXP3 and genetic susceptibility to thyroid autoimmunity: an association analysis in Caucasian and Japanese cohorts. J Autoimmun 28 (2007) 201-207
34. hi T regulatory cells. Blood 108 (2006) 253-261